NovaBay Pharmaceuticals, Inc. 8-K

What Happened

• NovaBay Pharmaceuticals, Inc. announced that on February 11, 2026 its board approved a 1-for-5 reverse stock split, implemented pursuant to stockholder approval received at the annual meeting on October 16, 2025. The Company issued a press release reporting the action.

Key Details

• Reverse split ratio: 1-for-5 (one new share for every five outstanding shares).
• Shareholder approval date: October 16, 2025; board approval and announcement date: February 11, 2026.
• The Company filed a press release dated February 11, 2026 as Exhibit 99.1 to the Form 8-K.
• The filing includes standard forward-looking statements language and refers investors to the Company’s prior SEC filings (Form 10-Q/K and the September 23, 2025 proxy) for risk factors related to the reverse split.

Why It Matters

• A reverse stock split reduces the number of outstanding shares and proportionally increases the per-share price; it does not change the company’s overall market value in itself. For investors, this can affect per-share metrics, share count reporting, and trading liquidity.
• The filing alerts investors to the corporate action and points to existing disclosures on risks and potential impacts (see the Company’s recent SEC reports and proxy).